Rapha Pharmaceuticals operates a network of international pharmaceutical manufacturing facilities strategically located across multiple jurisdictions to support regional supply and global distribution. These facilities are established and registered with their respective national health authorities, including operations in the United States, Guatemala, and Mexico, and are structured to comply with applicable regulatory frameworks and recognized international quality standards. This diversified manufacturing footprint enables Rapha Pharmaceuticals to maintain operational resilience, regulatory alignment across markets, and scalable production capabilities while ensuring consistent quality, safety, and reliability in the medicines it produces worldwide.

Rapha Pharmaceuticals specializes in the research, development, and manufacture of hormonal pharmaceutical products, with a focused expertise spanning reproductive health, endocrine therapies, and hormone-based treatments across multiple dosage forms. The company has developed deep technical capabilities in hormonal formulation science, stability, and scalable manufacturing, enabling the reliable production of both established and innovative therapies that require precise dosing and rigorous quality control. Through this specialization, Rapha Pharmaceuticals supports clinicians, health systems, and patients worldwide with hormonally active medicines designed to meet stringent regulatory standards while addressing critical therapeutic needs across diverse global markets.